AstraZeneca and China's BioKangtai have entered into a licensing deal for AZ's COVID-19 vaccine candidate AZD1222, developed by the UK's University of Oxford, to supply the shots to China. The companies, which did not disclose the deal's financial terms, will also consider vaccine production for other countries, with AZ granting BioKangtai exclusive clinical development, manufacturing, and marketing rights in China.
AZ, BioKangtai ink COVID-19 vaccine licensing deal
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.